[Use of phosphaden in treating chronic ischemic heart disease]. 1979

V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova

The pharmacodynamics and pharmacotherapy of phosphaden (adenosine-5-monophosphate), a Soviet activator of energy metabolism, were studied in patients with chronic ischemic heart disease. Functional and biochemical methods were used. It was established that phosphaden is an effective drug in the treatment of chronic ischemic heart disease. The results of clinical, functional and biochemical examination support this conclusion.

UI MeSH Term Description Entries
D007273 Injections, Intramuscular Forceful administration into a muscle of liquid medication, nutrient, or other fluid through a hollow needle piercing the muscle and any tissue covering it. Intramuscular Injections,Injection, Intramuscular,Intramuscular Injection
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002908 Chronic Disease Diseases which have one or more of the following characteristics: they are permanent, leave residual disability, are caused by nonreversible pathological alteration, require special training of the patient for rehabilitation, or may be expected to require a long period of supervision, observation, or care (Dictionary of Health Services Management, 2d ed). For epidemiological studies chronic disease often includes HEART DISEASES; STROKE; CANCER; and diabetes (DIABETES MELLITUS, TYPE 2). Chronic Condition,Chronic Illness,Chronically Ill,Chronic Conditions,Chronic Diseases,Chronic Illnesses,Condition, Chronic,Disease, Chronic,Illness, Chronic
D003327 Coronary Disease An imbalance between myocardial functional requirements and the capacity of the CORONARY VESSELS to supply sufficient blood flow. It is a form of MYOCARDIAL ISCHEMIA (insufficient blood supply to the heart muscle) caused by a decreased capacity of the coronary vessels. Coronary Heart Disease,Coronary Diseases,Coronary Heart Diseases,Disease, Coronary,Disease, Coronary Heart,Diseases, Coronary,Diseases, Coronary Heart,Heart Disease, Coronary,Heart Diseases, Coronary
D004341 Drug Evaluation Any process by which toxicity, metabolism, absorption, elimination, preferred route of administration, safe dosage range, etc., for a drug or group of drugs is determined through clinical assessment in humans or veterinary animals. Evaluation Studies, Drug,Drug Evaluation Studies,Drug Evaluation Study,Drug Evaluations,Evaluation Study, Drug,Evaluation, Drug,Evaluations, Drug,Studies, Drug Evaluation,Study, Drug Evaluation
D004734 Energy Metabolism The chemical reactions involved in the production and utilization of various forms of energy in cells. Bioenergetics,Energy Expenditure,Bioenergetic,Energy Expenditures,Energy Metabolisms,Expenditure, Energy,Expenditures, Energy,Metabolism, Energy,Metabolisms, Energy
D005260 Female Females
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000249 Adenosine Monophosphate Adenine nucleotide containing one phosphate group esterified to the sugar moiety in the 2'-, 3'-, or 5'-position. AMP,Adenylic Acid,2'-AMP,2'-Adenosine Monophosphate,2'-Adenylic Acid,5'-Adenylic Acid,Adenosine 2'-Phosphate,Adenosine 3'-Phosphate,Adenosine 5'-Phosphate,Adenosine Phosphate Dipotassium,Adenosine Phosphate Disodium,Phosphaden,2' Adenosine Monophosphate,2' Adenylic Acid,5' Adenylic Acid,5'-Phosphate, Adenosine,Acid, 2'-Adenylic,Acid, 5'-Adenylic,Adenosine 2' Phosphate,Adenosine 3' Phosphate,Adenosine 5' Phosphate,Dipotassium, Adenosine Phosphate,Disodium, Adenosine Phosphate,Monophosphate, 2'-Adenosine,Phosphate Dipotassium, Adenosine,Phosphate Disodium, Adenosine

Related Publications

V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
August 1986, Vrachebnoe delo,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
November 1981, Voenno-meditsinskii zhurnal,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
November 1983, Klinicheskaia meditsina,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
January 1990, Vutreshni bolesti,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
February 1973, American heart journal,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
September 1984, Vrachebnoe delo,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
November 1984, Vrachebnoe delo,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
May 1982, Klinicheskaia meditsina,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
January 1978, Vutreshni bolesti,
V G Kukes, and E F Burian, and S M Sekamova, and M E Baganova, and T M Iudakova
February 2007, Clinical cardiology,
Copied contents to your clipboard!